Physician profile
Richard A Webber
NPI 1932279049
$6,015.02
in general payments reported to CMS, 2019-2025
29 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $447 · 2021: $720 · 2022: $1,146 · 2023: $1,134 · 2024: $995 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,204.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,041.45 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $900.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $615.36 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $555.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $534.91 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $371.34 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $321.24 | 2019-2020 | |
| Pfizer INC. | $299.71 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $179.32 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $174.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.04 | 2020-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $114.60 | 2022 | |
| Abbott Laboratories | $91.06 | 2023-2024 | Freestyle Libre 3 |
| Lundbeck LLC | $84.47 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $82.70 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $80.87 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $71.32 | 2021-2022 | |
| Astellas Pharma US INC | $62.31 | 2019-2023 | Veozah |
| Viatris Specialty LLC | $51.54 | 2025 | Yupelri |
| Exact Sciences Corporation | $47.15 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Collegium Pharmaceutical, INC. | $31.71 | 2023-2024 | Belbuca, Xtampza |
| Biohaven Pharmaceuticals, INC. | $28.62 | 2020-2021 | |
| Axsome Therapeutics, INC. | $24.86 | 2024 | Auvelity |
| Sanofi Pasteur INC. | $24.22 | 2023 | |
| Merck Sharp & Dohme LLC | $23.50 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.48 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $15.26 | 2025 | Eliquis |
| Idorsia Pharmaceuticals US INC | $14.86 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Webber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.